Matikainen T, Haavisto A M, Permi J, de Kretser D, Huhtaniemi I
Department of Physiology, University of Turku, Finland.
Clin Endocrinol (Oxf). 1994 Jun;40(6):743-50. doi: 10.1111/j.1365-2265.1994.tb02507.x.
No data are available on effects of long-term exposure to oestrogen on bioactivity of gonadotrophins in men. We studied the effects of a 6-month oestrogen therapy on serum FSH and LH bioactivity (B), immunoreactivity (I) and isohormone distribution, and on serum I-inhibin levels, in patients with prostatic carcinoma.
Eleven men with advanced prostatic cancer were studied, each receiving 160 mg of polyoestradiol phosphate (Estradurin) once a month intramuscularly for 6 months.
Serum samples were collected before, and after 2 and 6 months of oestrogen treatment. Serum B- and I-FSH levels were measured by immature rat granulosa cell bioassay and immunofluorometric (IFMA, Delfia) assay, respectively, and those of B- and I-LH by mouse interstitial cell bioassay and IFMA, respectively. Serum oestradiol (E2) concentrations were measured by IFMA assay, and serum testosterone (T) and inhibin levels by radioimmunoassay. Isoelectric focusing was used for fractionation of the FSH and LH isoforms.
The pretreatment levels of B-FSH and I-FSH were 84.7 +/- 21.6 and 11.4 +/- 3.2 IU/l (mean +/- SEM), respectively, and the B/I ratio of FSH was 8.3 +/- 1.0. The pretreatment levels of B-LH and I-LH were 23.5 +/- 3.2 and 10.1 +/- 2.3 IU/l, respectively, and the B/I ratio was 3.0 +/- 0.4. After 6 months of oestrogen therapy, B-FSH and I-FSH decreased to 37.5 +/- 8.1 (P < 0.05) and 1.3 +/- 0.3 IU/l (P < 0.01), respectively, but the B/I ratio of FSH increased to 28.5 +/- 4.2 (P < 0.05). B- and I-LH levels decreased in 6 months to 7.4 +/- 0.9 and 2.3 +/- 0.5 IU/l (P < 0.01), respectively, but no change was found in the B/I ratio of LH. Serum T levels decreased from 19.0 +/- 2.6 to 2.7 +/- 0.9 nmol/l (P < 0.01) during the 6-month treatment, and the respective E2 levels increased from 0.2 +/- 0.01 to 4.4 +/- 0.5 nmol/l (P < 0.01). Serum I-inhibin levels were analysed from eight patients. The levels at 0, 2 and 6 months were 0.81 +/- 0.09, 0.50 +/- 0.03 and 0.54 +/- 0.01 microgram/l, respectively. Gonadotrophins in the pretreatment and 6-month samples of four patients were analysed by isoelectric focusing. In FSH of all subjects, and in LH of three subjects, a shift from acidic to more basic isoforms occurred after oestrogen therapy. This is in keeping with the increase of the B/I ratio of FSH. With LH, the isoform shift occurred between fractions with similar B/I ratios, and hence there was no shift in the overall B/I ratio.
Oestrogen therapy of men suppressed bioactive and immunoreactive levels of gonadotrophins. The B/I ratio of FSH increased, and this increase was associated with a shift in the isohormone profile to more basic forms. In contrast, no change occurred in the B/I ratio of LH, even though changes in the isohormone profile were observed. Hence, not all changes in the isohormone distribution of gonadotrophins result in changes of the intrinsic in-vitro bioactivity.
目前尚无关于男性长期暴露于雌激素对促性腺激素生物活性影响的数据。我们研究了6个月雌激素治疗对前列腺癌患者血清促卵泡生成素（FSH）和促黄体生成素（LH）的生物活性（B）、免疫反应性（I）及同工激素分布，以及血清I-抑制素水平的影响。
研究了11例晚期前列腺癌男性患者，每人每月肌肉注射160mg多聚磷酸雌二醇（戊酸雌二醇），共6个月。
在雌激素治疗前、治疗2个月和6个月后采集血清样本。血清B-FSH和I-FSH水平分别通过未成熟大鼠颗粒细胞生物测定法和免疫荧光测定法（IFMA，DELFIA）测定，血清B-LH和I-LH水平分别通过小鼠间质细胞生物测定法和IFMA测定。血清雌二醇（E2）浓度通过IFMA测定，血清睾酮（T）和抑制素水平通过放射免疫测定。采用等电聚焦法对FSH和LH同工型进行分离。
治疗前B-FSH和I-FSH水平分别为84.7±21.6和11.4±3.2IU/L（均值±标准误），FSH的B/I比值为8.3±1.0。治疗前B-LH和I-LH水平分别为23.5±3.2和10.1±2.3IU/L，B/I比值为3.0±0.4。雌激素治疗6个月后，B-FSH和I-FSH分别降至37.5±8.1（P<0.05）和1.3±0.3IU/L（P<0.01），但FSH的B/I比值升至28.5±4.2（P<0.05）。6个月内B-LH和I-LH水平分别降至7.4±0.9和2.3±0.5IU/L（P<0.01），但LH的B/I比值无变化。6个月治疗期间血清T水平从19.0±2.6降至2.7±0.9nmol/L（P<0.01），相应的E2水平从0.2±0.01升至4.4±0.5nmol/L（P<0.01）。分析了8例患者的血清I-抑制素水平。0、2和6个月时的水平分别为0.81±0.09、0.
